JP2012525431A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012525431A5 JP2012525431A5 JP2012508752A JP2012508752A JP2012525431A5 JP 2012525431 A5 JP2012525431 A5 JP 2012525431A5 JP 2012508752 A JP2012508752 A JP 2012508752A JP 2012508752 A JP2012508752 A JP 2012508752A JP 2012525431 A5 JP2012525431 A5 JP 2012525431A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- pyrido
- unsubstituted
- salt
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 96
- 150000003839 salts Chemical class 0.000 claims description 66
- 239000012453 solvate Substances 0.000 claims description 59
- -1 perhaloalkyl Chemical group 0.000 claims description 55
- 125000000217 alkyl group Chemical group 0.000 claims description 40
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 30
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 22
- 125000005843 halogen group Chemical group 0.000 claims description 20
- 125000001072 heteroaryl group Chemical group 0.000 claims description 20
- 125000002541 furyl group Chemical group 0.000 claims description 14
- 125000002883 imidazolyl group Chemical group 0.000 claims description 14
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 14
- 125000002971 oxazolyl group Chemical group 0.000 claims description 14
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 14
- 125000004076 pyridyl group Chemical group 0.000 claims description 14
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 14
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 14
- 125000001544 thienyl group Chemical group 0.000 claims description 14
- 125000003118 aryl group Chemical group 0.000 claims description 13
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 12
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims description 11
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims description 11
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- 125000004442 acylamino group Chemical group 0.000 claims description 8
- 125000005102 carbonylalkoxy group Chemical group 0.000 claims description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- 125000003107 substituted aryl group Chemical group 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 6
- 125000000623 heterocyclic group Chemical group 0.000 claims description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 6
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims description 4
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 4
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 125000002252 acyl group Chemical group 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000000266 alpha-aminoacyl group Chemical group 0.000 claims description 4
- 150000001408 amides Chemical class 0.000 claims description 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 4
- 125000004104 aryloxy group Chemical group 0.000 claims description 4
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 claims description 4
- 125000005589 carbonylalkylenealkoxy group Chemical group 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 125000004001 thioalkyl group Chemical group 0.000 claims description 4
- 150000003573 thiols Chemical class 0.000 claims description 4
- PXSYMVMGRYBTRY-UHFFFAOYSA-N 2,8-dimethyl-5-[(2-phenyl-1,3-dioxolan-2-yl)methyl]-3,4-dihydro-1h-pyrido[4,3-b]indole Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CC1(C=2C=CC=CC=2)OCCO1 PXSYMVMGRYBTRY-UHFFFAOYSA-N 0.000 claims description 3
- KSHIBYPIOGCPDH-UHFFFAOYSA-N 2,8-dimethyl-5-[(2-pyridin-3-yl-1,3-dioxolan-2-yl)methyl]-3,4-dihydro-1h-pyrido[4,3-b]indole Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CC1(C=2C=NC=CC=2)OCCO1 KSHIBYPIOGCPDH-UHFFFAOYSA-N 0.000 claims description 3
- WIFQQALACNYNTA-UHFFFAOYSA-N 5-[[2-(4-fluorophenyl)-1,3-dioxolan-2-yl]methyl]-2,8-dimethyl-3,4-dihydro-1h-pyrido[4,3-b]indole Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CC1(C=2C=CC(F)=CC=2)OCCO1 WIFQQALACNYNTA-UHFFFAOYSA-N 0.000 claims description 3
- NXUKGYHIRFZZSE-UHFFFAOYSA-N 8-chloro-2-methyl-5-[[2-(2-methylpyridin-4-yl)-1,3-dioxolan-2-yl]methyl]-3,4-dihydro-1h-pyrido[4,3-b]indole Chemical compound C1N(C)CCC2=C1C1=CC(Cl)=CC=C1N2CC1(C=2C=C(C)N=CC=2)OCCO1 NXUKGYHIRFZZSE-UHFFFAOYSA-N 0.000 claims description 3
- XNSPQXHRNZQWTD-UHFFFAOYSA-N 8-chloro-2-methyl-5-[[2-(6-methylpyridin-3-yl)-1,3-dioxolan-2-yl]methyl]-3,4-dihydro-1h-pyrido[4,3-b]indole Chemical compound C1N(C)CCC2=C1C1=CC(Cl)=CC=C1N2CC1(C=2C=NC(C)=CC=2)OCCO1 XNSPQXHRNZQWTD-UHFFFAOYSA-N 0.000 claims description 3
- VAVLJFSBBMYFKS-UHFFFAOYSA-N 8-chloro-5-[[2-(4-chlorophenyl)-1,3-dioxolan-2-yl]methyl]-2-methyl-3,4-dihydro-1h-pyrido[4,3-b]indole Chemical compound C1N(C)CCC2=C1C1=CC(Cl)=CC=C1N2CC1(C=2C=CC(Cl)=CC=2)OCCO1 VAVLJFSBBMYFKS-UHFFFAOYSA-N 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- CEHPIEPEGHHJJZ-UHFFFAOYSA-N 2,8-dimethyl-5-[(2-pyrimidin-4-yl-1,3-dioxolan-2-yl)methyl]-3,4-dihydro-1h-pyrido[4,3-b]indole Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CC1(C=2N=CN=CC=2)OCCO1 CEHPIEPEGHHJJZ-UHFFFAOYSA-N 0.000 claims description 2
- SDDGVYKUUGHLJD-UHFFFAOYSA-N 2-(2,8-dimethyl-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl)-1-(4-fluorophenyl)-1-phenylethanol Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CC(O)(C=1C=CC(F)=CC=1)C1=CC=CC=C1 SDDGVYKUUGHLJD-UHFFFAOYSA-N 0.000 claims description 2
- UBFWYALTTULUDG-UHFFFAOYSA-N 2-cyclopropyl-5-[2-fluoro-2-(4-methoxyphenyl)propyl]-8-methyl-3,4-dihydro-1h-pyrido[4,3-b]indole Chemical compound C1=CC(OC)=CC=C1C(C)(F)CN1C2=CC=C(C)C=C2C2=C1CCN(C1CC1)C2 UBFWYALTTULUDG-UHFFFAOYSA-N 0.000 claims description 2
- YYBJLIFFKRGEED-UHFFFAOYSA-N 2-ethyl-5-(2-fluoro-2-pyridin-3-ylpropyl)-8-methyl-3,4-dihydro-1h-pyrido[4,3-b]indole Chemical compound C1N(CC)CCC2=C1C1=CC(C)=CC=C1N2CC(C)(F)C1=CC=CN=C1 YYBJLIFFKRGEED-UHFFFAOYSA-N 0.000 claims description 2
- CRBBHOGWBDLVRA-UHFFFAOYSA-N 2-methyl-5-[(2-pyridin-4-yl-1,3-dioxolan-2-yl)methyl]-3,4-dihydro-1h-pyrido[4,3-b]indole Chemical compound C1N(C)CCC2=C1C1=CC=CC=C1N2CC1(C=2C=CN=CC=2)OCCO1 CRBBHOGWBDLVRA-UHFFFAOYSA-N 0.000 claims description 2
- QXTAYFISWQSPRT-UHFFFAOYSA-N 3-(2,4-difluorophenyl)-4-(2,8-dimethyl-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl)butanoic acid Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CC(CC(O)=O)C1=CC=C(F)C=C1F QXTAYFISWQSPRT-UHFFFAOYSA-N 0.000 claims description 2
- WXTVXXFBPXVBTO-UHFFFAOYSA-N 4-(2,8-dimethyl-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl)-3-(2-fluorophenyl)-n-methylbutanamide Chemical compound C1=2CCN(C)CC=2C2=CC(C)=CC=C2N1CC(CC(=O)NC)C1=CC=CC=C1F WXTVXXFBPXVBTO-UHFFFAOYSA-N 0.000 claims description 2
- OPMKRVRPBZAAMY-UHFFFAOYSA-N 4-(2,8-dimethyl-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl)-3-(2-fluorophenyl)butanoic acid Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CC(CC(O)=O)C1=CC=CC=C1F OPMKRVRPBZAAMY-UHFFFAOYSA-N 0.000 claims description 2
- CMBIIHJHLILBSO-UHFFFAOYSA-N 4-(2,8-dimethyl-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl)-3-(4-fluorophenyl)-n-methylbutanamide Chemical compound C1=2CCN(C)CC=2C2=CC(C)=CC=C2N1CC(CC(=O)NC)C1=CC=C(F)C=C1 CMBIIHJHLILBSO-UHFFFAOYSA-N 0.000 claims description 2
- WPRCVURQRSQRDQ-UHFFFAOYSA-N 4-(2,8-dimethyl-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl)-3-(4-fluorophenyl)butanoic acid Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CC(CC(O)=O)C1=CC=C(F)C=C1 WPRCVURQRSQRDQ-UHFFFAOYSA-N 0.000 claims description 2
- NLHAWMARHNLPJU-UHFFFAOYSA-N 4-(2,8-dimethyl-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl)-3-pyridin-3-ylbutanoic acid Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CC(CC(O)=O)C1=CC=CN=C1 NLHAWMARHNLPJU-UHFFFAOYSA-N 0.000 claims description 2
- GFXZZEBQRNFDPE-UHFFFAOYSA-N 4-(8-chloro-2-methyl-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl)-3-(4-chlorophenyl)-n-methylbutanamide Chemical compound C1=2CCN(C)CC=2C2=CC(Cl)=CC=C2N1CC(CC(=O)NC)C1=CC=C(Cl)C=C1 GFXZZEBQRNFDPE-UHFFFAOYSA-N 0.000 claims description 2
- HFYNOYFHGWDKRQ-UHFFFAOYSA-N 4-(8-chloro-2-methyl-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl)-3-(4-chlorophenyl)butanoic acid Chemical compound C1N(C)CCC2=C1C1=CC(Cl)=CC=C1N2CC(CC(O)=O)C1=CC=C(Cl)C=C1 HFYNOYFHGWDKRQ-UHFFFAOYSA-N 0.000 claims description 2
- QNTGEWKKHKULDO-UHFFFAOYSA-N 4-(8-chloro-2-methyl-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl)-3-(4-methoxyphenyl)butanoic acid Chemical compound C1=CC(OC)=CC=C1C(CC(O)=O)CN1C2=CC=C(Cl)C=C2C2=C1CCN(C)C2 QNTGEWKKHKULDO-UHFFFAOYSA-N 0.000 claims description 2
- ZHAOCYAINPJTBG-UHFFFAOYSA-N 4-(8-chloro-2-methyl-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl)-3-pyrimidin-4-ylbutanoic acid Chemical compound C1N(C)CCC2=C1C1=CC(Cl)=CC=C1N2CC(CC(O)=O)C1=CC=NC=N1 ZHAOCYAINPJTBG-UHFFFAOYSA-N 0.000 claims description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- JHTDVHAJMMAAIW-UHFFFAOYSA-N 5-(2-fluoro-2-pyridin-4-ylpropyl)-2,8-dimethyl-3,4-dihydro-1h-pyrido[4,3-b]indole Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CC(C)(F)C1=CC=NC=C1 JHTDVHAJMMAAIW-UHFFFAOYSA-N 0.000 claims description 2
- GOVOMCQLELOXOH-UHFFFAOYSA-N 5-(2-fluoro-2-pyrimidin-4-ylpropyl)-2,8-dimethyl-3,4-dihydro-1h-pyrido[4,3-b]indole Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CC(C)(F)C1=CC=NC=N1 GOVOMCQLELOXOH-UHFFFAOYSA-N 0.000 claims description 2
- YQQMLLFAAOPODD-UHFFFAOYSA-N 5-[2-(4-chlorophenyl)-2-fluoropropyl]-2,8-dimethyl-3,4-dihydro-1h-pyrido[4,3-b]indole Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CC(C)(F)C1=CC=C(Cl)C=C1 YQQMLLFAAOPODD-UHFFFAOYSA-N 0.000 claims description 2
- MCXPOPAHXQJKEF-UHFFFAOYSA-N 5-[2-fluoro-2-(2-methylpyridin-4-yl)propyl]-2,8-dimethyl-3,4-dihydro-1h-pyrido[4,3-b]indole Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CC(C)(F)C1=CC=NC(C)=C1 MCXPOPAHXQJKEF-UHFFFAOYSA-N 0.000 claims description 2
- RKPPXNINQHFRTD-UHFFFAOYSA-N 5-[2-fluoro-2-(4-fluorophenyl)propyl]-2,8-dimethyl-3,4-dihydro-1h-pyrido[4,3-b]indole Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CC(C)(F)C1=CC=C(F)C=C1 RKPPXNINQHFRTD-UHFFFAOYSA-N 0.000 claims description 2
- WDTMBTSDKCPDBW-UHFFFAOYSA-N 8-chloro-2-methyl-5-[2-(3-methylpyridin-4-yl)butyl]-3,4-dihydro-1H-pyrido[4,3-b]indole Chemical compound CCC(CN1C2=C(CN(C)CC2)C2=CC(Cl)=CC=C12)C1=C(C)C=NC=C1 WDTMBTSDKCPDBW-UHFFFAOYSA-N 0.000 claims description 2
- FQGQMNNNLBPFDH-UHFFFAOYSA-N 8-chloro-2-methyl-5-[[2-(3-methylpyridin-4-yl)-1,3-dioxolan-2-yl]methyl]-3,4-dihydro-1h-pyrido[4,3-b]indole Chemical compound C1N(C)CCC2=C1C1=CC(Cl)=CC=C1N2CC1(C=2C(=CN=CC=2)C)OCCO1 FQGQMNNNLBPFDH-UHFFFAOYSA-N 0.000 claims description 2
- ARAICNLSMVFMIA-UHFFFAOYSA-N 8-chloro-5-(2-fluoro-2-pyridin-3-ylpropyl)-2-methyl-3,4-dihydro-1h-pyrido[4,3-b]indole Chemical compound C1N(C)CCC2=C1C1=CC(Cl)=CC=C1N2CC(C)(F)C1=CC=CN=C1 ARAICNLSMVFMIA-UHFFFAOYSA-N 0.000 claims description 2
- DVDZIMYMWCQZOA-UHFFFAOYSA-N 8-chloro-5-(2-fluoro-2-pyridin-4-ylpropyl)-2-methyl-3,4-dihydro-1h-pyrido[4,3-b]indole Chemical compound C1N(C)CCC2=C1C1=CC(Cl)=CC=C1N2CC(C)(F)C1=CC=NC=C1 DVDZIMYMWCQZOA-UHFFFAOYSA-N 0.000 claims description 2
- ZVDZIWOYYUERJP-UHFFFAOYSA-N 8-chloro-5-[2-(2,4-difluorophenyl)-2-fluoropropyl]-2-methyl-3,4-dihydro-1h-pyrido[4,3-b]indole Chemical compound C1N(C)CCC2=C1C1=CC(Cl)=CC=C1N2CC(C)(F)C1=CC=C(F)C=C1F ZVDZIWOYYUERJP-UHFFFAOYSA-N 0.000 claims description 2
- ZYCJYYFQJHKNMC-UHFFFAOYSA-N 8-chloro-5-[2-fluoro-2-(6-methylpyridin-3-yl)propyl]-2-methyl-3,4-dihydro-1h-pyrido[4,3-b]indole Chemical compound C1N(C)CCC2=C1C1=CC(Cl)=CC=C1N2CC(C)(F)C1=CC=C(C)N=C1 ZYCJYYFQJHKNMC-UHFFFAOYSA-N 0.000 claims description 2
- VPCVVOOGNDRGFN-UHFFFAOYSA-N 8-chloro-5-[[2-(2-chlorophenyl)-1,3-dioxolan-2-yl]methyl]-2-methyl-3,4-dihydro-1h-pyrido[4,3-b]indole Chemical compound C1N(C)CCC2=C1C1=CC(Cl)=CC=C1N2CC1(C=2C(=CC=CC=2)Cl)OCCO1 VPCVVOOGNDRGFN-UHFFFAOYSA-N 0.000 claims description 2
- MQTGBDFTUKTJSY-UHFFFAOYSA-N CCC(CN1C2=C(CN(CC2)C)C3=C1C=CC(=C3)Cl)C4=CN=C(C=C4)C Chemical compound CCC(CN1C2=C(CN(CC2)C)C3=C1C=CC(=C3)Cl)C4=CN=C(C=C4)C MQTGBDFTUKTJSY-UHFFFAOYSA-N 0.000 claims description 2
- DQBINRGWLUXRHX-UHFFFAOYSA-N CCC(CN1C2=C(CN(CC2)CC)C3=C1C=CC(=C3)C)C4=CC(=NC=C4)C Chemical compound CCC(CN1C2=C(CN(CC2)CC)C3=C1C=CC(=C3)C)C4=CC(=NC=C4)C DQBINRGWLUXRHX-UHFFFAOYSA-N 0.000 claims description 2
- 102000000543 Histamine Receptors Human genes 0.000 claims description 2
- 108010002059 Histamine Receptors Proteins 0.000 claims description 2
- 125000004423 acyloxy group Chemical group 0.000 claims description 2
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims description 2
- 230000019771 cognition Effects 0.000 claims description 2
- 208000010877 cognitive disease Diseases 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- NCKQTYFVEMJDIE-UHFFFAOYSA-N ethyl 4-(2,8-dimethyl-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl)-3-(4-fluorophenyl)butanoate Chemical compound C1=2CCN(C)CC=2C2=CC(C)=CC=C2N1CC(CC(=O)OCC)C1=CC=C(F)C=C1 NCKQTYFVEMJDIE-UHFFFAOYSA-N 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 4
- OUNFKARXQGDBIP-UHFFFAOYSA-N 4-(2,8-dimethyl-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl)-3-pyridin-4-ylbutanoic acid Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CC(CC(O)=O)C1=CC=NC=C1 OUNFKARXQGDBIP-UHFFFAOYSA-N 0.000 claims 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 0 *C(*)(*)C[n]1c2ccc(*)cc2c2c1CCN(*)C2 Chemical compound *C(*)(*)C[n]1c2ccc(*)cc2c2c1CCN(*)C2 0.000 description 19
- NXUDRZAGTICPOO-UHFFFAOYSA-N 5-(2-fluoro-2-pyridin-4-ylethyl)-2,8-dimethyl-3,4-dihydro-1h-pyrido[4,3-b]indole Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CC(F)C1=CC=NC=C1 NXUDRZAGTICPOO-UHFFFAOYSA-N 0.000 description 1
- QSWKMJOKNSYKKR-UHFFFAOYSA-N 8-chloro-5-[2-fluoro-2-(3-methylpyridin-4-yl)propyl]-2-propan-2-yl-3,4-dihydro-1h-pyrido[4,3-b]indole Chemical compound C1N(C(C)C)CCC2=C1C1=CC(Cl)=CC=C1N2CC(C)(F)C1=CC=NC=C1C QSWKMJOKNSYKKR-UHFFFAOYSA-N 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1135/NUM/2009 | 2009-04-29 | ||
| IN1135MU2009 | 2009-04-29 | ||
| US18125909P | 2009-05-26 | 2009-05-26 | |
| US61/181,259 | 2009-05-26 | ||
| PCT/US2010/033055 WO2011019417A1 (en) | 2009-04-29 | 2010-04-29 | Pyrido [4, 3-b] indoles and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012525431A JP2012525431A (ja) | 2012-10-22 |
| JP2012525431A5 true JP2012525431A5 (enExample) | 2013-06-27 |
| JP5827943B2 JP5827943B2 (ja) | 2015-12-02 |
Family
ID=43586371
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012508752A Expired - Fee Related JP5827943B2 (ja) | 2009-04-29 | 2010-04-29 | ピリド［４，３−ｂ］インドールおよびその使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US8741919B2 (enExample) |
| EP (1) | EP2424366B1 (enExample) |
| JP (1) | JP5827943B2 (enExample) |
| CN (1) | CN102480956B (enExample) |
| AU (1) | AU2010282990B2 (enExample) |
| BR (1) | BRPI1006608A2 (enExample) |
| CA (1) | CA2760516A1 (enExample) |
| WO (1) | WO2011019417A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2007139634A (ru) | 2007-10-25 | 2009-04-27 | Сергей Олегович Бачурин (RU) | Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения |
| RU2544856C2 (ru) | 2008-01-25 | 2015-03-20 | Сергей Олегович Бачурин | НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| WO2009120717A2 (en) * | 2008-03-24 | 2009-10-01 | Medivation Technologies, Inc. | Pyrido [3, 4-b] indoles and methods of use |
| CL2009000725A1 (es) | 2008-03-24 | 2009-05-29 | Medivation Technologies Inc | Compuestos derivados de heterociclos con uniones puente sustituidos, moduladores de receptores adrenergicos, de serotonina, de dopamina y de histaminas; composicion farmaceutica; kit farmaceutico; y su uso en el tratamiento del trastorno cognitivo y trastorno psicotico. |
| CA2742320A1 (en) | 2008-10-31 | 2010-05-06 | Medivation Technologies, Inc. | Pyrido[4,3-b]indoles containing rigid moieties |
| CA2742322A1 (en) | 2008-10-31 | 2010-05-06 | Medivation Technologies, Inc. | Azepino[4,5-b]indoles and methods of use |
| US8362277B2 (en) | 2009-01-09 | 2013-01-29 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
| CN102405043B (zh) | 2009-01-09 | 2017-08-22 | 得克萨斯州大学系统董事会 | 前神经原性化合物 |
| US9162980B2 (en) | 2009-01-09 | 2015-10-20 | Board Of Regents Of The University Of Texas System | Anti-depression compounds |
| US9962368B2 (en) | 2009-01-09 | 2018-05-08 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
| WO2010093425A1 (en) | 2009-02-11 | 2010-08-19 | Sepracor Inc. | Histamine h3 inverse agonists and antagonists and methods of use thereof |
| CA2760516A1 (en) | 2009-04-29 | 2011-02-17 | Medivation Technologies, Inc. | Pyrido[4,3-b]indoles and methods of use |
| CN102480955B (zh) * | 2009-04-29 | 2015-08-05 | 梅迪维新技术公司 | 吡啶并[4,3-b]吲哚类和使用方法 |
| WO2011038161A1 (en) | 2009-09-23 | 2011-03-31 | Medivation Technologies, Inc. | Pyrido[4,3-b]indoles and methods of use |
| US9079904B2 (en) | 2009-09-23 | 2015-07-14 | Medivation Technologies, Inc. | Pyrido[3,4-B]indoles and methods of use |
| EP2480081A4 (en) | 2009-09-23 | 2013-03-06 | Medivation Technologies Inc | Bridged heterocyclic compounds and methods for their use |
| WO2011103485A1 (en) | 2010-02-18 | 2011-08-25 | Medivation Technologies, Inc. | Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
| WO2011103460A1 (en) | 2010-02-18 | 2011-08-25 | Medivation Technologies, Inc. | Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]ondole derivatives and methods of use |
| US9034865B2 (en) | 2010-02-18 | 2015-05-19 | Medivation Technologies, Inc. | Pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use |
| WO2011103430A1 (en) | 2010-02-19 | 2011-08-25 | Medivation Technologies, Inc. | Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
| WO2012006419A2 (en) | 2010-07-07 | 2012-01-12 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
| US9434747B2 (en) | 2011-02-18 | 2016-09-06 | Medivation Technologies, Inc. | Methods of treating diabetes |
| WO2012112964A2 (en) | 2011-02-18 | 2012-08-23 | Medivation Technologies, Inc. | PYRIDO[4,3-b]INDOLE AND PYRIDO[3,4-b]INDOLE DERIVATIVES AND METHODS OF USE |
| US9199985B2 (en) | 2011-02-18 | 2015-12-01 | Medivation Technologies, Inc. | Compounds and methods for treatment of hypertension |
| US8791132B2 (en) | 2011-02-18 | 2014-07-29 | Medivation Technologies, Inc. | Compounds and methods for treatment of hypertension |
| JP6272773B2 (ja) * | 2011-11-29 | 2018-01-31 | ナンジン アルゲン ファルマ カンパニー リミテッドＮａｎｊｉｎｇ Ａｌｌｇｅｎ Ｐｈａｒｍａ Ｃｏ． Ｌｔｄ． | Ｈｄａｃ６阻害剤・抗腫瘍剤用複素環アミド化合物 |
| WO2014031165A1 (en) * | 2012-08-22 | 2014-02-27 | Medivation Technologies, Inc. | Compounds and methods of treating diabetes |
| WO2014031986A1 (en) | 2012-08-24 | 2014-02-27 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
| WO2015070237A1 (en) | 2013-11-11 | 2015-05-14 | Board Of Regents Of The University Of Texas System | Neuroprotective chemicals and methods for identifying and using same |
| WO2015070234A2 (en) | 2013-11-11 | 2015-05-14 | Board Of Regents Of The University Of Texas System | Neuroprotective compounds and use thereof |
| BR112020016008A2 (pt) * | 2018-02-05 | 2020-12-15 | The Rockefeller University | Composto, método para inibir uma resposta inflamatória em um paciente, método para inibir inflamação em um paciente, método para inibir expressão de interferon ativada por dsdna em um mamífero, método para tratar metástase de câncer em um paciente e formulação farmacêutica |
| CA3196153A1 (en) * | 2020-09-24 | 2022-03-31 | Ventus Therapeutics U.S., Inc. | Pyrido[4,3-b]indole derivatives and their use as pharmaceuticals |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3484449A (en) | 1966-05-12 | 1969-12-16 | Hoffmann La Roche | Certain substituted phenyl amino-ethylpyridine intermediates |
| US3409628A (en) | 1966-05-12 | 1968-11-05 | Hoffmann La Roche | 5-(3-pyridylethyl)pyridoindole derivatives |
| US3646045A (en) | 1968-09-10 | 1972-02-29 | Hoffmann La Roche | Intermediates for 5-(4-pyridylethyl)-pyridoindole derivatives |
| US3502688A (en) | 1968-09-10 | 1970-03-24 | Hoffmann La Roche | 5-(4-pyridylethyl)-pyridoindole derivatives |
| JPS5143863B2 (enExample) | 1973-06-18 | 1976-11-25 | ||
| US4754038A (en) | 1987-02-26 | 1988-06-28 | American Home Products Corporation | Carboline histamine H1 antagonists |
| EP0353983B1 (en) | 1988-08-02 | 1996-05-29 | Glaxo Group Limited | Lactam derivatives |
| RU2140417C1 (ru) | 1995-10-17 | 1999-10-27 | Институт физиологически активных веществ РАН | Производные гидрированных пиридо(4,3-b)индолов, способы их получения, фармацевтическая композиция и способ лечения |
| RU2106864C1 (ru) | 1995-10-23 | 1998-03-20 | Николай Серафимович Зефиров | Средство для лечения болезни альцгеймера |
| DE10030375A1 (de) | 2000-06-21 | 2002-01-03 | Bayer Ag | Verwendung von MTP-Inhibitoren zur Senkung von ppTRL |
| JP2005526691A (ja) | 2001-08-08 | 2005-09-08 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 治療剤１Ｈ−ピリド［４，３−ｂ］インドール |
| US7736889B2 (en) | 2003-06-10 | 2010-06-15 | The United States Of America As Represented By The Secretary Of The Navy | Fluidic force discrimination |
| EA014956B1 (ru) | 2004-12-17 | 2011-04-29 | ГЛЕНМАРК ФАРМАСЬЮТИКАЛС Эс.Эй. | Гетероциклические соединения, применяемые для лечения воспалительных и аллергических нарушений |
| AU2006275694A1 (en) * | 2005-07-28 | 2007-02-08 | Bristol-Myers Squibb Company | Substituted tetrahydro-1H-pyrido(4,3,b)indoles as serotonin receptor agonists and antagonists |
| US20070117835A1 (en) | 2005-10-04 | 2007-05-24 | David Hung | Methods and compositions for treating Huntington's disease |
| RU2338537C2 (ru) * | 2006-01-25 | 2008-11-20 | Сергей Олегович Бачурин | СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ШИЗОФРЕНИИ НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b)ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ |
| JP2010504337A (ja) | 2006-09-20 | 2010-02-12 | メディベイション ニューロロジー， インコーポレイテッド | イヌの認知機能障害症候群の治療のためのディメボン（ｄｉｍｅｂｏｎ）などの水素化ピリド［４，３−ｂ］インドール |
| JP2010504338A (ja) | 2006-09-20 | 2010-02-12 | メディベイション ニューロロジー， インコーポレイテッド | 筋萎縮性側索硬化症（ＡＬＳ）の治療のための水素化ピリド［４，３−ｂ］インドール |
| SG178000A1 (en) | 2006-10-27 | 2012-02-28 | Medivation Neurology Inc | Methods and combination therapies for treating alzheimer's disease |
| RU2329044C1 (ru) | 2006-11-16 | 2008-07-20 | Андрей Александрович Иващенко | Лиганды 5-ht6 рецепторов, фармацевтическая композиция, способ ее получения и лекарственное средство |
| RU2334514C1 (ru) | 2006-12-01 | 2008-09-27 | Институт физиологически активных веществ Российской Академии наук | СРЕДСТВО ДЛЯ УЛУЧШЕНИЯ КОГНИТИВНЫХ ФУНКЦИЙ И ПАМЯТИ НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО (4,3-b) ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ |
| RU2340342C2 (ru) | 2006-12-07 | 2008-12-10 | Сергей Олегович Бачурин | СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ОСТРЫХ И ХРОНИЧЕСКИХ НАРУШЕНИЙ МОЗГОВОГО КРОВООБРАЩЕНИЯ, В ТОМ ЧИСЛЕ ИНСУЛЬТА, НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО[4,3-b]ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ |
| RU2338745C1 (ru) | 2007-03-21 | 2008-11-20 | Андрей Александрович Иващенко | ЗАМЕЩЕННЫЕ 2,3,4,5-ТЕТРАГИДРО-1Н-ПИРИДО[4,3-b]ИНДОЛЫ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ |
| JP5580731B2 (ja) | 2007-04-05 | 2014-08-27 | アンドレイ・アレクサンドロビッチ・イワシェンコ | 置換された２，３，４，５−テトラヒドロ−１ｈ−ピリド［４，３−ｂ］インドール、その製造のための方法及び使用 |
| RU2339637C1 (ru) * | 2007-04-05 | 2008-11-27 | Андрей Александрович Иващенко | Блокаторы гистаминного рецептора для фармацевтических композиций, обладающих противоаллергическим и аутоиммунным действием |
| AU2008257152A1 (en) | 2007-05-25 | 2008-12-04 | Medivation Neurology, Inc. | Methods and compositions for stimulating cells |
| RU2338533C1 (ru) | 2007-06-28 | 2008-11-20 | Сергей Олегович Бачурин | СРЕДСТВО, ОБЛАДАЮЩЕЕ АНКСИОЛИТИЧЕСКИМ ДЕЙСТВИЕМ, НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b)ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ |
| CN101842010A (zh) | 2007-08-01 | 2010-09-22 | 梅迪维新神经学公司 | 使用抗精神病的组合治疗产品来治疗精神分裂症的方法和组合物 |
| MX2010003149A (es) | 2007-09-20 | 2010-11-10 | D2E Llc | Derivados que contienen fluor de pirido[4,3-b]indoles hidrogenados con propiedades neuroprotectoras y de mejoramiento de cognicion, proceso de preparacion y uso. |
| WO2009039420A1 (en) | 2007-09-21 | 2009-03-26 | Medivation Neurology, Inc. | Methods and compositions for treating neuronal death mediated ocular diseases |
| RU2007139634A (ru) | 2007-10-25 | 2009-04-27 | Сергей Олегович Бачурин (RU) | Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения |
| WO2009082268A2 (ru) * | 2007-12-21 | 2009-07-02 | Alla Chem, Llc | ЛИГАНДЫ α-АДРЕНОЦЕПТОРОВ, ДОПАМИНОВЫХ, ГИСТАМИНОВЫХ, ИМИДАЗОЛИНОВЫХ И СЕРОТОНИНОВЫХ РЕЦЕПТОРОВ И ИХ ПРИМЕНЕНИЕ |
| RU2544856C2 (ru) | 2008-01-25 | 2015-03-20 | Сергей Олегович Бачурин | НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| WO2009111540A1 (en) | 2008-03-04 | 2009-09-11 | Medivation Neurology, Inc. | Methods for preparing pyridylethyl-substituted carbolines |
| WO2009120717A2 (en) | 2008-03-24 | 2009-10-01 | Medivation Technologies, Inc. | Pyrido [3, 4-b] indoles and methods of use |
| CL2009000725A1 (es) | 2008-03-24 | 2009-05-29 | Medivation Technologies Inc | Compuestos derivados de heterociclos con uniones puente sustituidos, moduladores de receptores adrenergicos, de serotonina, de dopamina y de histaminas; composicion farmaceutica; kit farmaceutico; y su uso en el tratamiento del trastorno cognitivo y trastorno psicotico. |
| WO2009135091A1 (en) | 2008-04-30 | 2009-11-05 | Medivation Technologies, Inc. | Use of asenapine and related compounds for the treatment of neuronal or non-neuronal diseases or conditions |
| CN101640878B (zh) | 2008-07-29 | 2011-08-31 | 华为技术有限公司 | 一种确定漫游用户终端移动性的方法及装置 |
| WO2010014758A1 (en) | 2008-07-30 | 2010-02-04 | Edison Pharmaceuticals, Inc. | Use of hydrogenated pyrido[4,3-b] indoles for the treatment of oxidative stress |
| CA2742320A1 (en) | 2008-10-31 | 2010-05-06 | Medivation Technologies, Inc. | Pyrido[4,3-b]indoles containing rigid moieties |
| CA2742322A1 (en) | 2008-10-31 | 2010-05-06 | Medivation Technologies, Inc. | Azepino[4,5-b]indoles and methods of use |
| CA2760516A1 (en) | 2009-04-29 | 2011-02-17 | Medivation Technologies, Inc. | Pyrido[4,3-b]indoles and methods of use |
| CN102480955B (zh) * | 2009-04-29 | 2015-08-05 | 梅迪维新技术公司 | 吡啶并[4,3-b]吲哚类和使用方法 |
| WO2011014695A1 (en) | 2009-07-29 | 2011-02-03 | Medivation Technologies, Inc. | New 2,3,4,5-tetrahydro-1h-pyrido[4,3-b] indoles and methods of use |
| EP2480081A4 (en) | 2009-09-23 | 2013-03-06 | Medivation Technologies Inc | Bridged heterocyclic compounds and methods for their use |
| US9079904B2 (en) | 2009-09-23 | 2015-07-14 | Medivation Technologies, Inc. | Pyrido[3,4-B]indoles and methods of use |
| WO2011038161A1 (en) | 2009-09-23 | 2011-03-31 | Medivation Technologies, Inc. | Pyrido[4,3-b]indoles and methods of use |
| WO2011038162A1 (en) | 2009-09-23 | 2011-03-31 | Medivation Technologies, Inc. | Pyrido(3,4-b)indoles and methods of use |
| US20130172320A1 (en) | 2010-02-18 | 2013-07-04 | Sarvajit Chakravarty | Pyrido [4,3-b] indole and pyrido [3,4-b] indole derivatives and methods of use |
| US9034865B2 (en) | 2010-02-18 | 2015-05-19 | Medivation Technologies, Inc. | Pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use |
| WO2011103460A1 (en) | 2010-02-18 | 2011-08-25 | Medivation Technologies, Inc. | Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]ondole derivatives and methods of use |
| WO2011103485A1 (en) | 2010-02-18 | 2011-08-25 | Medivation Technologies, Inc. | Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
| WO2011103430A1 (en) | 2010-02-19 | 2011-08-25 | Medivation Technologies, Inc. | Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
| WO2011103448A1 (en) | 2010-02-19 | 2011-08-25 | Medivation Technologies, Inc. | Methods and compositions for treating psychotic disorders using antipsychotic combination therapy |
| US8791132B2 (en) | 2011-02-18 | 2014-07-29 | Medivation Technologies, Inc. | Compounds and methods for treatment of hypertension |
| US9434747B2 (en) | 2011-02-18 | 2016-09-06 | Medivation Technologies, Inc. | Methods of treating diabetes |
| US9199985B2 (en) | 2011-02-18 | 2015-12-01 | Medivation Technologies, Inc. | Compounds and methods for treatment of hypertension |
| WO2012112964A2 (en) | 2011-02-18 | 2012-08-23 | Medivation Technologies, Inc. | PYRIDO[4,3-b]INDOLE AND PYRIDO[3,4-b]INDOLE DERIVATIVES AND METHODS OF USE |
| WO2014031170A1 (en) | 2012-08-22 | 2014-02-27 | Medivation Technologies, Inc. | Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
| WO2014031165A1 (en) | 2012-08-22 | 2014-02-27 | Medivation Technologies, Inc. | Compounds and methods of treating diabetes |
-
2010
- 2010-04-29 CA CA2760516A patent/CA2760516A1/en not_active Abandoned
- 2010-04-29 AU AU2010282990A patent/AU2010282990B2/en not_active Ceased
- 2010-04-29 EP EP10808471.6A patent/EP2424366B1/en not_active Not-in-force
- 2010-04-29 JP JP2012508752A patent/JP5827943B2/ja not_active Expired - Fee Related
- 2010-04-29 BR BRPI1006608-0A patent/BRPI1006608A2/pt not_active IP Right Cessation
- 2010-04-29 WO PCT/US2010/033055 patent/WO2011019417A1/en not_active Ceased
- 2010-04-29 CN CN201080029084.1A patent/CN102480956B/zh not_active Expired - Fee Related
- 2010-04-29 US US13/318,124 patent/US8741919B2/en not_active Expired - Fee Related
-
2013
- 2013-03-08 US US13/791,862 patent/US8927571B2/en not_active Expired - Fee Related